United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Invests $10.29 Million in Boston Scientific Corporation $BSX

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund acquired a new stake in Boston Scientific Corporation (NYSE:BSX) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 107,888 shares of the medical equipment provider’s stock, valued at approximately $10,287,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BSX. Egerton Capital UK LLP lifted its position in Boston Scientific by 223.7% in the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock valued at $518,660,000 after acquiring an additional 3,671,548 shares in the last quarter. Alphinity Investment Management Pty Ltd bought a new position in Boston Scientific in the 4th quarter valued at approximately $252,918,000. Marshall Wace LLP lifted its position in Boston Scientific by 30.7% in the 3rd quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock valued at $956,680,000 after acquiring an additional 2,301,383 shares in the last quarter. Credit Agricole S A bought a new position in Boston Scientific in the 3rd quarter valued at approximately $204,812,000. Finally, Arrowstreet Capital Limited Partnership lifted its position in Boston Scientific by 28.1% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 8,367,398 shares of the medical equipment provider’s stock valued at $816,909,000 after acquiring an additional 1,837,480 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Insider Transactions at Boston Scientific

In related news, Director Cheryl Pegus acquired 1,770 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the purchase, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Edward J. Ludwig acquired 3,580 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $56.68 per share, with a total value of $202,914.40. Following the completion of the purchase, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. This represents a 16.44% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 9,800 shares of company stock worth $554,012 in the last three months. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Price Performance

NYSE BSX opened at $49.12 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The stock has a market capitalization of $73.01 billion, a price-to-earnings ratio of 20.55, a PEG ratio of 0.93 and a beta of 0.62. Boston Scientific Corporation has a 1-year low of $48.41 and a 1-year high of $109.50. The business’s fifty day moving average price is $60.69 and its 200-day moving average price is $78.84.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific’s revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities analysts predict that Boston Scientific Corporation will post 3.37 earnings per share for the current year.

Boston Scientific announced that its board has approved a stock repurchase program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on BSX. Daiwa Securities Group cut Boston Scientific from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $55.00 price objective (down from $75.00) on shares of Boston Scientific in a research report on Thursday. Argus raised Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Barclays lowered their price target on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a report on Thursday. Finally, The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and an average target price of $87.46.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific advanced several clinical programs, including updates on its FARAPULSE pulsed-field ablation study and a diabetic neuropathy trial that is nearing a key data milestone, which could support future product growth. Boston Scientific Advances FARAPULSE PFA Study in Atrial Fibrillation
• Positive Sentiment: Unusual options activity showed heavy call buying in BSX, suggesting some traders are positioning for a rebound.
• Neutral Sentiment: Wall Street brokerage consensus still leans bullish overall, with the stock holding a “Moderate Buy” rating from analysts.
• Neutral Sentiment: Boston Scientific continues to work on its device pipeline and capital deployment strategy, which may help offset current franchise weakness over time. Boston Scientific (BSX) Device Succeeds in Over 93% of Patients in Its Pivotal Trial
• Negative Sentiment: Wells Fargo downgraded Boston Scientific to Equal Weight from Overweight, citing uncertainty around the EP business and the WATCHMAN franchise. Wells Fargo cuts Boston Scientific to ’Equal Weight’ on Watchman slowdown
• Negative Sentiment: Management’s reduced 2026 organic growth outlook and comments about slower WATCHMAN procedures and competitive pressure in electrophysiology were the main catalysts behind the stock’s decline. Boston Scientific shares fall 10% on Watchman weakness, competitive pressures

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.